Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Hydrochloric Acid | HCID 313 | — |
| Reactant | Bis-(1H-imidazol-2-YL)-methanone | HCID 5250894 | — |
| Reactant | 3-(Piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one | HCID 11042597 | — |
| Reactant | HCID 57794652 | HCID 57794652 | — |
| Solvent | Ethyl Acetate | HCID 8857 | — |
| Product | HCID 11285018 | HCID 11285018 | — |
Reaction Steps
tert-Butyl 1-(1-(3-fluorobenzyl)-4-methyl-1H-imidazol-2-yl)-2-(7-methyl-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-5-yl)ethylcarbamate (20.0 mg, 0.034 mmol) was dissolved in a minimum amount of ethyl acetate, and treated with hydrochloric acid (4 N in dioxane, 1.0 mL). The mixture was stirred under nitrogen for 3 days. After removal of the solvents, the crude mixture was treated with diethyl ether to give a precipitate which was filtered. The resulting solid was dissolved in dimethylformamide (1.0 mL), cooled to 0° C., and treated with carbonyl diimidazole (6.0 mg, 0.037 mmol, 1.1 equiv) and N′N-diisopropylethylamine (24.3 μL, 3 equiv). The reaction was stirred for 5 min at 0° C., warmed to room temperature, stirred for 10 min, and treated with 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one (8.5 mg, 0.037 mmol, 1.1 equiv). The mixture was stirred at room temperature overnight. The solvent was evaporated and the residue purified by column chromatography to afford 16.1 mg (74%, 2 steps). 1H-NMR (CD3OD, 500 MHz) δ 1.50-1.68 (m, 4H), 2.27 (s, 3H), 2.46 (s, 3H), 2.77 (m, 2H), 3.20 (m, 2H), 4.01-4.16 (m, 2H), 4.20 (s, 2H), 4.32-4.43 (m, 1H), 5.13-5.22 (m, 2H), 6.60-6.67 (m, 2H), 6.70 (s, 1H), 6.76-6.86 (m, 2H), 6.87-6.94 (m, 1H), 6.96 (dd, J=8.3, 6.7, 1H), 7.07-7.14 (m, 2H), 7.16 (dd, J=7.9, 7.6, 1H), 7.25 (s, 1H), 7.92 (s, 1H). Mass spec.: 621.4 (MH)+.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07569578B2 |
|---|
| Source dataset | uspto-grants-2009_08 |
|---|
| ORD ID | ord-674ca6d11b034f6ab9972dbc52744887 |
|---|
| Source note | uspto-grants-2009_08 |
|---|